Tags : RGX-314

Pharma

Regenxbio Signs an Exclusive Worldwide Option and License Agreement with

Shots: Clearside to receive ~$34M as development milestones, ~$102M commercial milestones, option exercise fee and royalties on sales of product utilizing SCS microinjector. Regenxbio to get an option to receive an exclusive WW commercial license with rights to sublicense Clearside’s SCS microinjector to deliver AAV gene therapies for wet AMD, DR and other chronic anti-VEGF […]Read More